Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$15.81 USD
-0.08 (-0.50%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $15.69 -0.12 (-0.76%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
Avadel Pharmaceuticals PLC. [AVDL]
Reports for Purchase
Showing records 21 - 40 ( 45 total )
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
2Q21: FT218 October PDUFA Nears; Stock Reflects Overblown Approvability Concern, In Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Jazz Suit Not a Surprise; Doesn?t Trigger FDA Delay; Case Unlikely to Merit a Preliminary Injunction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Nearing Mid-Cycle Review With No Indication of IPRelated FT218 Approval Impediments; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Stock Doesn?t Reflect Incremental De-Risking of IP Certification Issue; Raise to $17 on Better Narcolepsy Market Pricing
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
3Q20: Year-End FT218 Filing Plan Confirmed; Fears of Approval Roadblocks Overblown; Strong Buy Here
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
2Q20: We Project FT218 NDA Around Year-End; Well-Funded and Undervalued; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Hospital Portfolio Sold as Laser focus is on FT218; Reiterate Buy and $15 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
We initiate coverage with a Buy rating and $15 price target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Dropping Coverage due to reallocate our research resources
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
3Q17 Recap - In-Line Quarter; Focus Shifts to Noctiva
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
Neutral on Noctiva; Positive on Sodium Oxybate and Eclat
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Avadel Pharmaceuticals PLC.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.